|
1
|
Jo JH, Kim YT, Choi HS, Kim HG, Lee HS,
Choi YW, Kim DU, Lee KH, Kim EJ, Han JH, et al: Efficacy of GV1001
with gemcitabine/capecitabine in previously untreated patients with
advanced pancreatic ductal adenocarcinoma having high serum eotaxin
levels (KG4/2015): An open-label, randomised, Phase 3 trial. Br J
Cancer. 130:43–52. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Primrose JN, Fox RP, Palmer DH, Malik HZ,
Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, et
al: Capecitabine compared with observation in resected biliary
tract cancer (BILCAP): A randomised, controlled, multicentre, phase
3 study. Lancet Oncol. 20:663–673. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Knikman JE, Rosing H, Guchelaar HJ, Cats A
and Beijnen JH: A review of the bioanalytical methods for the
quantitative determination of capecitabine and its metabolites in
biological matrices. Biomed Chromatogr. 34:e47322020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alzahrani SM, Al Doghaither HA, Al-Ghafari
AB and Pushparaj PN: 5-Fluorouracil and capecitabine therapies for
the treatment of colorectal cancer (Review). Oncol Rep. 50:1752023.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Z, Li X, Yang Y, Zhang F, Li M and
Chen W, Gao S and Chen W: A sensitive and efficient method for
determination of capecitabine and its five metabolites in human
plasma based on one-step liquid-liquid extraction. J Anal Methods
Chem. 2019:93717902019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
King TL, Voon PJ, Yuen KH and Mohamed Noor
DA: Hand-foot syndrome in cancer patients on capecitabine:
Examining prevalence, impacts, and associated risk factors at a
cancer centre in Malaysia. Support Care Cancer. 32:3452024.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Queiroz MVR, de Medeiros ACTR, Toledo
SP, de Abreu Sarmenghi KD and de Vasconcellos VF: Hand-foot
syndrome caused by capecitabine: incidence, risk factors and the
role of dermatological evaluation. Ecancermedicalscience.
16:13902022.PubMed/NCBI
|
|
8
|
Ahn HR, Lee SK, Youn HJ, Yun SK and Lee
IJ: Stevens-Johnson syndrome and concurrent hand foot syndrome
during treatment with capecitabine: A case report. World J Clin
Cases. 9:4279–4284. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong
D and Zeng S: Possible pathways of capecitabine-induced hand-foot
syndrome. Chem Res Toxicol. 29:1591–1601. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hiromoto S, Kawashiri T, Yamanaka N,
Kobayashi D, Mine K, Inoue M, Uchida M and Shimazoe T: Use of
omeprazole, the proton pump inhibitor, as a potential therapy for
the capecitabine-induced hand-foot syndrome. Sci Rep. 11:89642021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu W, Huang Z, Chen S, Lv H, Chen X, Lei
J, Ke C, Hong C, Wei Y, Su R, et al: The effectiveness of
EVOSKIN(R)Palm and sole moisturizing cream in treating
capecitabine-associated hand-foot syndrome: A randomized
double-blind clinical trial. Ann Palliat Med. 10:3009–3017. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schag CC, Heinrich RL and Ganz PA:
Karnofsky performance status revisited: Reliability, validity, and
guidelines. J Clin Oncol. 2:187–193. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Freites-Martinez A, Santana N,
Arias-Santiago S and Viera A: Using the common terminology criteria
for adverse events (CTCAE-Version 5.0) to evaluate the severity of
adverse events of anticancer therapies. Actas Dermosifiliogr (Engl
Ed). 112:90–92. 2021.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
14
|
R Core Team, . R: A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna: 2021
|
|
15
|
Li C, Zhang J, Wu R, Liu Y, Hu X, Yan Y
and Ling X: A novel strategy for rapidly and accurately screening
biomarkers based on ultraperformance liquid chromatography-mass
spectrometry metabolomics data. Anal Chim Acta. 1063:47–56. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karaman I: Preprocessing and pretreatment
of metabolomics data for statistical analysis. Adv Exp Med Biol.
965:145–161. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang J, Zhao X, Lu X, Lin X and Xu G: A
data preprocessing strategy for metabolomics to reduce the mask
effect in data analysis. Front Mol Biosci. 2:42015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liang JH, Lin Y, Ouyang T, Tang W, Huang
Y, Ye W, Zhao JY, Wang ZN and Ma CC: Nuclear magnetic
resonance-based metabolomics and metabolic pathway networks from
patient-matched esophageal carcinoma, adjacent noncancerous tissues
and urine. World J Gastroenterol. 25:3218–3230. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Berry L and Venkatesan P:
Aciclovir-induced neurotoxicity: Utility of CSF and serum CMMG
levels in diagnosis. J Clin Virol. 61:608–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Perez Valero I, Cabello A, Ryan P, De La
Fuente-Moral S, Santos I, Vivancos MJ, Gonzalez A, Gorgolas M,
Cuevas G, Diaz De Santiago A, et al: Randomized trial evaluating
the neurotoxicity of dolutegravir/abacavir/lamivudine and its
reversibility after switching to
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: GESIDA
9016. Open Forum Infect Dis. 7:ofaa4822020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tarpey AE, Loranger A, Plambeck R and
Malesker MA: Neurotoxicity secondary to valacyclovir. J Pharm
Technol. 38:251–252. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vonberg FW, Dawson A, Scott G and Davies
N: Aciclovir-induced neurotoxicity. Pract Neurol. 23:157–159. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garbiec E, Cielecka-Piontek J, Kowalowka
M, Holubiec M and Zalewski P: Genistein-opportunities related to an
interesting molecule of natural origin. Molecules. 27:8152022.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park JH, Hwang JW, Lee HJ, Jang GM, Jeong
YJ, Cho J, Seo J and Hoe HS: Lomerizine inhibits LPS-mediated
neuroinflammation and tau hyperphosphorylation by modulating NLRP3,
DYRK1A, and GSK3α/β. Front Immunol. 14:11509402023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei TT, Chandy M, Nishiga M, Zhang A,
Kumar KK, Thomas D, Manhas A, Rhee S, Justesen JM, Chen IY, et al:
Cannabinoid receptor 1 antagonist genistein attenuates
marijuana-induced vascular inflammation. Cell. 185:2387–2389.e23.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hannun YA and Obeid LM: Principles of
bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol
Cell Biol. 9:139–150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
van Meer G, Voelker DR and Feigenson GW:
Membrane lipids: Where they are and how they behave. Nat Rev Mol
Cell Biol. 9:112–124. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dennis EA and Norris PC: Eicosanoid storm
in infection and inflammation. Nat Rev Immunol. 15:511–523. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brosnan JT: Interorgan amino acid
transport and its regulation. J Nutr. 133 (6 Suppl 1):2068S–2072S.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
DeBerardinis RJ and Chandel NS:
Fundamentals of cancer metabolism. Sci Adv. 2:e16002002016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arlemalm A, Hellden A, Karlsson L and
Carlsson B: Rapid determination of acyclovir, its main metabolite
9-carboxymethoxymethylguanine, ganciclovir, and penciclovir in
human serum using LC-MS/MS. Biomed Chromatogr. 36:e53152022.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abuhelwa Z, Beran A, Venkataramany BS,
Hinch BT and Assaly R: Concurrent nephrotoxicity and neurotoxicity
induced by oral valacyclovir in a patient with previously normal
kidney function. Cureus. 14:e236932022.PubMed/NCBI
|
|
33
|
Aboelezz A and Mahmoud SH: Acyclovir
dosing in herpes encephalitis: A scoping review. J Am Pharm Assoc
(2003). 64:1020402024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Takeda S, Ueno S, Zenda R, Muto K, Iseki K
and Harada K: Simultaneous analysis of acyclovir and its metabolite
using hydrophilic interaction liquid chromatography-tandem mass
spectrometry. J Anal Toxicol. 48:204–209. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Leger PD, Johnson DH, Robbins GK, Shafer
RW, Clifford DB, Li J, McLaren PJ and Haas DW: Genome-wide
association study of peripheral neuropathy with D-drug-containing
regimens in AIDS clinical trials Group protocol 384. J Neurovirol.
20:304–308. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bokore A, Korme B and Bayisa G:
Determinants of anti-retroviral regimen changes among HIV/AIDS
patients of east and west Wollega zone health institutions, Oromia
region, west Ethiopia: A cross-sectional study. BMC Pharmacol
Toxicol. 19:282018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dalakas MC: Peripheral neuropathy and
antiretroviral drugs. J Peripher Nerv Syst. 6:14–20. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Youle M: Acetyl-L-carnitine in
HIV-associated antiretroviral toxic neuropathy. CNS Drugs. 21
(Suppl 1):25–30; discussion 45–26. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dagan T, Sable C, Bray J and Gerschenson
M: Mitochondrial dysfunction and antiretroviral nucleoside analog
toxicities: What is the evidence? Mitochondrion. 1:397–412. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chantharakhit C and Sujaritvanichpong N:
Predictive factors for the development of capecitabine-induced
hand-foot syndrome: A retrospective observational cohort study. Ann
Med Surg (Lond). 86:73–77. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK,
Tham CK, Wong NS, Lo SK, Dent RA, Tan S, et al: Predictors of
hand-foot syndrome and pyridoxine for prevention of
capecitabine-induced hand-foot syndrome: A Randomized clinical
trial. JAMA Oncol. 3:1538–1545. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kwakman JJM, Simkens LHJ, van Rooijen JM,
van de Wouw AJ, Ten Tije AJ, Creemers GJM, Hendriks MP, Los M, van
Alphen RJ, Polee MB, et al: Randomized phase III trial of S-1
versus capecitabine in the first-line treatment of metastatic
colorectal cancer: SALTO study by the Dutch colorectal cancer
group. Ann Oncol. 28:1288–1293. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Santhosh A, Sharma A, Bakhshi S, Kumar A,
Sharma V, Malik PS, Pramanik R, Gogia A, Prasad CP, Sehgal T, et
al: Topical diclofenac for prevention of capecitabine-associated
hand-foot syndrome: A double-blind randomized controlled trial. J
Clin Oncol. 42:1821–1829. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lian S, Zhang X, Zhang Y and Zhao Q:
Pyridoxine for prevention of hand-foot syndrome caused by
chemotherapy agents: A meta-analysis. Clin Exp Dermatol.
46:629–635. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Azuma Y, Hata K, Sai K, Udagawa R,
Hirakawa A, Tohkin M, Ryushima Y, Makino Y, Yokote N, Morikawa N,
et al: Significant association between hand-foot syndrome and
efficacy of capecitabine in patients with metastatic breast cancer.
Biol Pharm Bull. 35:717–724. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen M, Chen J, Peng X, Xu Z, Shao J, Zhu
Y, Li G, Zhu H, Yang B, Luo P and He Q: The contribution of
keratinocytes in capecitabine-stimulated hand-foot-syndrome.
Environ Toxicol Pharmacol. 49:81–88. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guengerich FP and MacDonald JS: Applying
mechanisms of chemical toxicity to predict drug safety. Chem Res
Toxicol. 20:344–369. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Park SY, Kim MW, Kang JH, Hwang JH, Choi
H, Park J, Seong JK, Yoon YS and Oh SH: Loss of Ninjurin1
alleviates acetaminophen-induced liver injury via enhancing
AMPKα-NRF2 pathway. Life Sci. 350:1227822024. View Article : Google Scholar : PubMed/NCBI
|
